2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 689

Apolipoprotein L1 Risk Variants Associate with Hypertension and Nephritis Progression Despite Lower dsDNA Titers in Ghanaian Systemic Lupus Erythematous Patients
Abstract Number: 690

SSA Antibodies Are Associated with Valvular Abnormalities in SLE Patients without Clinical Cardiovascular Disease
Abstract Number: 691

Serum Anti-NR2 Has a Better Specificity Than Sensitivity in Diagnosing Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)
Abstract Number: 692

High Plasma Factor XIII Transglutaminase Activity Inversely Correlates with SLE Disease Activity Yet Associates with Higher Carotid Artery IMT and Low CD14+CD16+ Monocyte Levels
Abstract Number: 693

The Utility of a Rise in Anti – Double Stranded DNA Antibodies for Predicting Disease Flares in Systemic Lupus Erythematosus. a Meta-Analysis
Abstract Number: 694

Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Can Reflect Systemic Lupus Erythematosus Activity
Abstract Number: 695

Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies
Abstract Number: 696

An ANA Screening Assay Containing Multiple Antigens Increases the Sensitivity and Specificity of ANA Testing By Indirect Immunofluorescence
Abstract Number: 697

Does Erythrocyte Sedimentation Rate Reflect and Discriminate Flare from Infection in Systemic Lupus Erythematosus? Correlation with Clinical and Laboratory Parameters of Disease Activity
Abstract Number: 698

Selected Nailfold Videocapillaroscopy Changes Are Linked to SLE Onset in a Cohort of Uctd Subjects
Abstract Number: 699

Impact of Anti-RBP Antibodies on Disease Activity and Quality-of-Life in Immunosuppressant Naive Systemic Lupus Erythematosus
Abstract Number: 700

Variability in Method of Testing for Antinuclear Antibodies (ANA): A Survey of Participants in the College of American Pathologist’s (CAP) Proficiency Testing Program
Abstract Number: 701

Variability in ICAP (International Consensus on ANA Patterns) Pattern Reporting in Testing for Antinuclear Antibodies (ANA) By Indirect Immunofluorescence Assay (IFA)
Abstract Number: 702

Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus
Abstract Number: 703

Clinical Value of Autoantibodies for Lupus Myelitis and Its Subtypes: A Systematic Review

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].